athembio.com

What It Is

AthemBio is a privately held bioprocessing technology company based in Research Triangle Park, North Carolina, USA. Its goal is to address limited patient access caused by the high cost of biologics manufacturing. Strictly speaking, it is not a typical SaaS or enterprise software provider; instead, it offers next-generation single-use, continuous processing platforms for biopharmaceutical production.

Core Capabilities

Its core products include CORIg™, machroS™, and cRUSH™. CORIg™ is a single-use continuous centrifugation platform that emphasizes true continuous discharge, low shear, and gentle cell handling. The materials state that it can achieve 95-99% cell recovery and supports cultures ranging from 0.1 million to over 350 million cells/mL. machroS™ is a single-use chromatography platform designed for direct capture of targets from unclarified crude feed. It uses non-porous, chemically defined nanoparticles; the materials claim it can bind more than 90% of product within 30 seconds and significantly reduce mAb costs and batch time. cRUSH™ is a single-use continuous-flow mechanical lysis/homogenization system, emphasizing detergent-free operation, controllability, and better suitability for sensitive products such as viral vectors.

Pricing and Business Model

The website does not publish full pricing for its equipment or platforms. The machroS Discovery Kit is available for lab-scale validation of direct capture capabilities, but the online ordering system is currently being updated, so orders or quotations require contacting the team. As a result, its business model is closer to inquiry-based procurement of high-end bioprocessing equipment and consumables than to subscription-based SaaS.

Pros and Cons

Its strengths lie in product designs centered on continuous processing, automation, closed systems, single-use operation, and a small footprint. The portfolio addresses key bottlenecks such as cell retention, clarification replacement, direct capture, and cell lysis, making it especially relevant for high-density culture, mAb, CGT, vaccines, and viral vector use cases. The downside is that public information lacks customer case studies, third-party validation, purchasing and service terms, and enterprise-software-related details such as APIs, permissions, software integrations, or data security certifications.

Who It’s For and Access from China

It is better suited to biopharmaceutical companies, CDMOs, cell and gene therapy teams, and vaccine teams with clear needs around process cost reduction, production scale-up, or continuous manufacturing. The text does not specify access conditions from China, so actual network testing and the availability of supply chain and after-sales support should be used as the reference.